AIM ImmunoTech Inc. stock is up 10.64% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 39.29% of the previous 27 December’s closed higher than November.
AIM ImmunoTech Inc. focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS) It is also developing Ampligen for the. treatment of renal cell carcinoma, malignant melanoma,. non-small cell lung, ovarian, breast,. breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis